BTK-IN-24(NX-5948)|CAS 2649400-34-8|DC Chemicals

Cas No.:	2649400-34-8
Chemical Name:	BTK-IN-24
Synonyms:	2-Pyrazinecarboxamide, 3-[[4-[1-[[1-[6-[[[(3S)-2,6-dioxo-3-piperidinyl]amino]carbonyl]-3-pyridinyl]-4-piperidinyl]methyl]-4-piperidinyl]phenyl]amino]-5-[(3R)-3-(3-methyl-2-oxo-1-imidazolidinyl)-1-piperidinyl]-;3-((4-(1-((1-(6-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)-5-((R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide;BTK-IN-24
SMILES:	C1(C(N)=O)=NC=C(N2CCC[C@@H](N3C(=O)N(C)CC3)C2)N=C1NC1=CC=C(C2CCN(CC3CCN(C4=CC=C(C(N[C@H]5CCC(=O)NC5=O)=O)N=C4)CC3)CC2)C=C1
Formula:	C₄₂H₅₄N₁₂O₅
M.Wt:	806.955567836761
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC67514	Abd110	Abd110 (compound 42i) is a PROTAC molecule derived from lenalidomide that specifically targets ATR kinase for degradation. This compound demonstrates remarkable selectivity, effectively reducing both ATR and phospho-ATR levels while sparing related DNA damage response kinases ATM and DNA-PKcs.
DC67513	MS8847	MS8847 represents a novel PROTAC molecule that selectively targets EZH2 for degradation by recruiting the VHL E3 ubiquitin ligase complex. This compound mediates potent, proteasome-dependent elimination of EZH2, demonstrating significant anti-proliferative effects against both AML and TNBC cell lines.
DC67512	PROTAC BRD4 Degrader-21	PROTAC BRD4 Degrader-21 (Compound 74) is a potent and selective degrader of BRD4, demonstrating robust tumor growth suppression in mouse xenograft models. Its efficacy supports its potential as a promising candidate for anticancer drug development.
DC67462	YJ1206	YJ1206 is an orally bioavailable PROTAC compound that selectively degrades CDK12 and CDK13, demonstrating potent activity (IC50 = 12.55 nM) in VCaP cells. It induces DNA damage, triggers apoptosis, and drives tumor regression in treatment-resistant prostate cancer PDX models, highlighting its therapeutic potential.
DC67177	BTK-IN-29	BTK-IN-29 (compound 14) is an inhibitor of Btk.
DC67098	cis-AGB1	Cis-AGB1 is a negative control for AGB1 . Exhibits no significant VHL binding affinity.
DC60681	SD-436	SD-436 is a highly potent and selective STAT3 degrader with DC50 of 0.1 nM in human PBMCs and displays >10,000-fold degradation selectivity for STAT3 over other STAT proteins.
DC67029	KT-413	KT-413 (example I-3) is a potent IRAK degrader.
DC65811	KT-253	KT-253 is a potent small molecule that stabilizes p53 while simultaneously acting as a PROTAC to degrade MDM2 (DC50 = 0.4 nM). It demonstrates strong antiproliferative effects in RS4;11 leukemia cells (IC50 = 0.3 nM), inducing G2/M cell cycle arrest and apoptosis. In vivo studies confirm its antitumor activity in mouse models.
DC65810	KT-333	KT-333 is a first-in-class molecular glue that induces selective degradation of STAT3 via the ubiquitin-proteasome system by simultaneously engaging STAT3 and the VHL E3 ligase. This novel mechanism enables potent STAT3 depletion with minimal off-target effects, demonstrating strong anti-tumor activity in hematologic malignancies.